Trending Now
Cerus Corporation (NASDAQ:CERS) Announces Study Results Demonstrating How the INTERCEPT Blood...
SARS-CoV-2 is the causative agent for COVID-19, the pandemic which has kept the whole world on its toes. It has not only claimed millions...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Exelixis Inc. (NASDAQ:EXEL) Commences Phase 3 CONTACT-01 Evaluating Combination of Cabozantinib...
Exelixis Inc. (NASDAQ:EXEL) has announced the start of the third phase vital CONTACT-01 cabozantinib (CABOMETYX) study combined with atezolizumab in metastatic non-small cell lung...
MAKE IT MODERN
LATEST REVIEWS
The Eco-Friendly Bull Market (BE, ECOX, ECL, NEE)
The drumbeat around renewable energy and “green” stocks is deafening in recent action, with millennials in charge of the market, launching the likes of...
MAKE IT MODERN
PERFORMANCE TRAINING
iBiO Inc. (NYSEAMERICAN:IBIO) Enters Agreement To Produce ATB Therapeutics’ Antibody-Toxin Fusion Proteins
Biologics contract development and manufacturing organization (CDMO), iBiO Inc. (NYSEAMERICAN:IBIO) has announced the signing of its first Statement of Work under a Master Services...
Actinium Pharmaceuticals (ATNM): Poised for Growth? Targeted Radiotherapy Conditioning Agent Shows Promise
Actinium Pharmaceuticals (ATNM) shares saw slight volatility on Tuesday, closing at $8.81 (-0.34%). However, recent announcements concerning the company's Iomab-ACT project could...
Applied Genetic Technologies Corporation (NASDAQ: AGTC) Announce Interim Results of Ongoing Phase 1/2 Dose...
Applied Genetic Technologies Corporation (NASDAQ: AGTC) has reported interim three-month paediatric data and further adult safety findings to almost 24 months from the ongoing...
Nabriva Therapeutics Plc (NASDAQ:NBRV) Announced Q3 2020 Results And Updates On SIVEXTRO And XENLETA
Nabriva Therapeutics plc (NASDAQ:NBRV) has reported financial results for the quarter ended September 30, 2020, and also offered a business update.
Nabriva enhances sales team...
Adaptive Biotechnologies Secures Key Regulatory Approval in Europe, Boosting ClonoSEQ
Adaptive Biotechnologies (ADPT), a company dedicated to translating the immune system's genetics into clinical solutions, recently announced a significant milestone: clonoSEQ®, its...
MAKE IT MODERN
